Skip to main content
Erschienen in: Supportive Care in Cancer 2/2018

19.09.2017 | Original Article

What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed: a retrospective case-control study at an Australian tertiary hospital

verfasst von: Saira Sanjida, Kelly Mulvogue, Joanne Shaw, Jeremy Couper, David Kissane, Sallie-Anne Pearson, Melanie A. Price, Monika Janda

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer patients are often prescribed antidepressants, but little data is available about whether the type and dose are similar to prescriptions to patients with other chronic diseases. This study compared the prescription practices of antidepressants to cancer and non-cancer inpatients at a major Australian tertiary hospital and assessed side effects and potential drug-drug interactions.

Methods

Inpatients diagnosed with cancer within the past 12 months and prescribed antidepressants were age and gender matched to inpatients with other chronic disease conditions. Data from 75 cancer and 75 non-cancer inpatients were extracted.

Results

Antidepressants were prescribed to cancer and non-cancer patients, respectively, for the treatment of depression (n = 50 vs n = 59), other mental health problems (n = 8 vs n = 11, p < 0.67) or unspecified reasons (n = 17 vs n = 5, p < 0.02). Mirtazapine (n = 11/75) was most commonly prescribed to cancer patients followed by duloxetine (n = 9/75). Desvenlafaxine (n = 15/75) was prescribed most commonly to non-cancer inpatients, followed by mirtazapine (n = 11/75). Four cancer patients and three non-cancer patients had documented adverse side effects from antidepressants. About one-third of cancer patients (n = 23/75) and about a quarter of non-cancer patients (n = 18/75) were prescribed other medicines with the potential for drug-drug interactions with antidepressants.

Conclusions

Antidepressants were prescribed for a range of indications in all patients, but more commonly for unspecified reasons among the cancer patients. Future prospective studies that monitor antidepressant prescribing to cancer patients should ascertain details of the indication, pathways to prescription and differences in type, dose or schedule depending on prescribing medical practitioner.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171CrossRef GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171CrossRef
2.
Zurück zum Zitat Hert M, Correll CU, Bobes J et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77CrossRef Hert M, Correll CU, Bobes J et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77CrossRef
3.
Zurück zum Zitat Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 23:2215–2224CrossRefPubMed Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 23:2215–2224CrossRefPubMed
4.
Zurück zum Zitat Gallagher J, Parle M, Cairns D (2002) Appraisal and psychological distress six months after diagnosis of breast cancer. Br J Health Psychol 7:365–376CrossRefPubMed Gallagher J, Parle M, Cairns D (2002) Appraisal and psychological distress six months after diagnosis of breast cancer. Br J Health Psychol 7:365–376CrossRefPubMed
5.
Zurück zum Zitat Neilson KA, Pollard AC, Boonzaier AM et al (2010) Psychological distress (depression and anxiety) in people with head and neck cancers. Med J Aus 193(5):S52–S57 Neilson KA, Pollard AC, Boonzaier AM et al (2010) Psychological distress (depression and anxiety) in people with head and neck cancers. Med J Aus 193(5):S52–S57
6.
Zurück zum Zitat Desplenter F, Bond C, Watson M et al (2012) Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case–control study. Br J Cancer 107:1644–1651CrossRefPubMedPubMedCentral Desplenter F, Bond C, Watson M et al (2012) Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case–control study. Br J Cancer 107:1644–1651CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mehnert A, Brähler E, Faller H et al (2014) Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 32(31):3540–3546CrossRefPubMed Mehnert A, Brähler E, Faller H et al (2014) Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 32(31):3540–3546CrossRefPubMed
9.
Zurück zum Zitat Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 314(17):1818–1831CrossRefPubMedPubMedCentral Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 314(17):1818–1831CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Brelin S, Loge JH, Skurtveit S et al (2013) Antidepressants to cancer patients during the last year of life—a population-based study. Psychooncology 22:506–514CrossRefPubMed Brelin S, Loge JH, Skurtveit S et al (2013) Antidepressants to cancer patients during the last year of life—a population-based study. Psychooncology 22:506–514CrossRefPubMed
11.
Zurück zum Zitat Kerr MP (1994) Antidepressant prescribing: a comparison between general practitioners and psychiatrists. Br J Gen Prac 44:275–276 Kerr MP (1994) Antidepressant prescribing: a comparison between general practitioners and psychiatrists. Br J Gen Prac 44:275–276
12.
Zurück zum Zitat McManus P, Mant A, Mitchell P, Britt H, Dudley J (2003) Use of antidepressants by general practitioners and psychiatrists in Australia. Aust N Z J of Psychiatry 37:184–189CrossRef McManus P, Mant A, Mitchell P, Britt H, Dudley J (2003) Use of antidepressants by general practitioners and psychiatrists in Australia. Aust N Z J of Psychiatry 37:184–189CrossRef
14.
Zurück zum Zitat Braun IM, Rao SR, Meyer FL, Fedele G (2014) Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls. Cancer 120:1–7CrossRef Braun IM, Rao SR, Meyer FL, Fedele G (2014) Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls. Cancer 120:1–7CrossRef
15.
Zurück zum Zitat Jones SMW, Rosenberg D, Ludman E, Arterburn D (2015) Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer. Support Care Cancer 23:3005–3009CrossRefPubMedPubMedCentral Jones SMW, Rosenberg D, Ludman E, Arterburn D (2015) Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer. Support Care Cancer 23:3005–3009CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ng CG, Boks MPM, Smeets HM, Zainal NZ, Niek J (2013) Prescription patterns for psychotropic drugs in cancer patients: a large population study in the Netherlands. Psychooncology 22:762–767CrossRefPubMed Ng CG, Boks MPM, Smeets HM, Zainal NZ, Niek J (2013) Prescription patterns for psychotropic drugs in cancer patients: a large population study in the Netherlands. Psychooncology 22:762–767CrossRefPubMed
17.
Zurück zum Zitat Butow P, Price MA, Shaw JM et al (2015) Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. Psychooncology 24(9):987–1001CrossRefPubMed Butow P, Price MA, Shaw JM et al (2015) Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. Psychooncology 24(9):987–1001CrossRefPubMed
22.
Zurück zum Zitat Bruce N, Pope D, Stanistreet D (2008) Quantitative methods for health research: a practical interactive guide to epidemiology and statistics. Wiley-Blackwell Publishing, NJCrossRef Bruce N, Pope D, Stanistreet D (2008) Quantitative methods for health research: a practical interactive guide to epidemiology and statistics. Wiley-Blackwell Publishing, NJCrossRef
23.
Zurück zum Zitat Rose S, van der Laan M (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat 5(1):1–24CrossRefPubMedCentral Rose S, van der Laan M (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat 5(1):1–24CrossRefPubMedCentral
24.
Zurück zum Zitat Nursing 2007 dangerous drug interactions (2007) Lippincott Williams & Wilkins. USA Nursing 2007 dangerous drug interactions (2007) Lippincott Williams & Wilkins. USA
25.
Zurück zum Zitat Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE, Edgerton S (1998) Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 16(4):1594–1600CrossRefPubMed Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE, Edgerton S (1998) Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 16(4):1594–1600CrossRefPubMed
26.
Zurück zum Zitat Walker J, Hansen CH, Martin P et al (2014) Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 1:343–350CrossRefPubMed Walker J, Hansen CH, Martin P et al (2014) Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 1:343–350CrossRefPubMed
27.
Zurück zum Zitat Travado L, Breitbart W, Grassi L et al (2016) 2015 President’s Plenary International Psycho-oncology Society: psychosocial care as a human rights issue-challenges and opportunities. Psychooncology. 2016 Aug 17. https://doi.org/10.1002/pon.4209 Travado L, Breitbart W, Grassi L et al (2016) 2015 President’s Plenary International Psycho-oncology Society: psychosocial care as a human rights issue-challenges and opportunities. Psychooncology. 2016 Aug 17. https://​doi.​org/​10.​1002/​pon.​4209
28.
Zurück zum Zitat Juurlink DN, Herrmann N, Szalai JP, Kopp A, Redelmeier DA (2004) Medical illness and the risk of suicide in the elderly. Arch Intern Med 164(11):1179–1184CrossRefPubMed Juurlink DN, Herrmann N, Szalai JP, Kopp A, Redelmeier DA (2004) Medical illness and the risk of suicide in the elderly. Arch Intern Med 164(11):1179–1184CrossRefPubMed
29.
Zurück zum Zitat Ng CG, Mohamed S, Wern TY, Haris A, Zainal NZ, Sulaiman AH (2014) Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia. Asian Pac J Cancer Prev 15:4261–4264CrossRefPubMed Ng CG, Mohamed S, Wern TY, Haris A, Zainal NZ, Sulaiman AH (2014) Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia. Asian Pac J Cancer Prev 15:4261–4264CrossRefPubMed
30.
Zurück zum Zitat Zhao L, Li X, Zhang Z et al (2014) Prevalence, correlates and recognition of depression in Chinese inpatients with cancer. Gen Hosp Psychiatry 36:477–482CrossRefPubMed Zhao L, Li X, Zhang Z et al (2014) Prevalence, correlates and recognition of depression in Chinese inpatients with cancer. Gen Hosp Psychiatry 36:477–482CrossRefPubMed
31.
Zurück zum Zitat Farriols C, Ferrandez O, Planas J, Ortiz P, Mojal S, Ruiz AI (2012) Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag 43(5):945–952CrossRef Farriols C, Ferrandez O, Planas J, Ortiz P, Mojal S, Ruiz AI (2012) Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag 43(5):945–952CrossRef
32.
Zurück zum Zitat Freynhagen R, Muth-Selbach U, Lipfert P et al (2006) The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 22(2):257–264CrossRefPubMed Freynhagen R, Muth-Selbach U, Lipfert P et al (2006) The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 22(2):257–264CrossRefPubMed
33.
Zurück zum Zitat Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195CrossRefPubMed Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195CrossRefPubMed
34.
Zurück zum Zitat Kast RE (2001) Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9(6):469–470CrossRefPubMed Kast RE (2001) Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9(6):469–470CrossRefPubMed
35.
Zurück zum Zitat Iosifescu DV, Bankier B, Fava M (2004) Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 6(3):193–201CrossRefPubMed Iosifescu DV, Bankier B, Fava M (2004) Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 6(3):193–201CrossRefPubMed
36.
Zurück zum Zitat Chan A, Ng TR, Yap KY (2012) Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin on Drug Metab Toxicol 8(2):173–199CrossRef Chan A, Ng TR, Yap KY (2012) Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin on Drug Metab Toxicol 8(2):173–199CrossRef
37.
Zurück zum Zitat van Leeuwen RW, Brundel DH, Neef C et al (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071–1078CrossRefPubMedPubMedCentral van Leeuwen RW, Brundel DH, Neef C et al (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071–1078CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Nersesyan H, Slavin KV (2007) Current approach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag 3(3):381–400PubMedPubMedCentral Nersesyan H, Slavin KV (2007) Current approach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag 3(3):381–400PubMedPubMedCentral
39.
Zurück zum Zitat Pearson S, Abrahamowicz M, Srasuebkul P, Buckley NA (2015) Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiology and Drug Safe 24:600–609CrossRef Pearson S, Abrahamowicz M, Srasuebkul P, Buckley NA (2015) Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiology and Drug Safe 24:600–609CrossRef
Metadaten
Titel
What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed: a retrospective case-control study at an Australian tertiary hospital
verfasst von
Saira Sanjida
Kelly Mulvogue
Joanne Shaw
Jeremy Couper
David Kissane
Sallie-Anne Pearson
Melanie A. Price
Monika Janda
Publikationsdatum
19.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3876-4

Weitere Artikel der Ausgabe 2/2018

Supportive Care in Cancer 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.